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(MI+ADSCs: 43.85.6%; MI+PBS: 37.23.0%). ShPHD2-ADSCs exerted signiﬁ-
cantly more protection (infarct size: 22.63.0%; LVEF: 67.36.8%; P<0.05 vs.
MI+ADSCs). PHD2 silencing induced greater ADSC survival (survival rate at 7 days
post-transplantation: shPHD2-ADSCs: 14.74.2% vs. ADSCs: 3.40.8%, P<0.05),
which was abolished by HIF-1alpha silencing. None of the ADSCs gave rise to
cardiomyocytes, and ADSC-induced cardioprotection was mainly induced by para-
crine function. Conditioned medium from shPHD2-ADSCs decreased cardiomyocyte
apoptosis. Insulin-like growth factor-1 (IGF-1) levels were 3.8 times higher in the
conditioned medium of shPHD2-ADSCs than ADSCs, and depletion of IGF-1
attenuated the cardioprotective effects of shPHD2-ADSC-conditioned medium.
NF-kappaB activation was induced by shPHD2 to stimulate IGF-1 secretion via
binding to the IGF-1 gene promoter. A combination of HIF-1alpha silencing and IGF-
1 neutralization blocked the beneﬁcial effects of shPHD2-ADSCs for MI. Similar
ﬁndings were observed with BM-MSCs.
Conclusions: PHD2 silencing promotes stem cell survival in infarcted hearts and
enhances their paracrine function to protect cardiomyocytes. Its prosurvival effect on
stem cells is HIF-1alpha dependent, while it enhances stem cell paracrine function
through NF-kappaB-mediated IGF-1 upregulation. PHD2 silencing in stem cells may
be a novel strategy for enhancing the effectiveness of stem cell therapy after MI.
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Objectives: To investigate the role of Interluekin1 receptor-associated kinase-4
(IRAK4), which plays an essential role in the innate immune system, in cardiac
remodeling induced by pressure overload and elucidate the underlying mechanisms.
Methods: In vivo studies were performed using IRAK4 heterozygous knockout
(IRAK4+/-) mice and wild type (IRAK4+/+) mice. Models of cardiac remodeling were
induced by aortic banding (AB). Cardiac remodeling was evaluated by Echocardi-
ography, catheter-based measurements of hemodynamic parameters and histological
analysis. In vitro studies were performed using H9c2 cardiomyoblasts with over-
expression of IRAK4 or not. Models of cardiomyoblast hypertrophy were induced by
Angiotension II (AngII) treatment. Cardiomyoblast hypertrophy was evaluated by
immunoﬂuorescent staining of a-actin. mRNA and protein expression were detected
by real-time PCR and Western Blot analysis.
Results: IRAK4 was upregulated in pressure overload induced mice heart. IRAK4+/-
mice exhibited exacerbated cardiac hypertrophy, dysfunction and ﬁbrosis after 4
weeks of aortic banding (AB) compared with that in wild-type mice. Furthermore,
enhanced activation of the MEK-ERK1/2, p38 and NFkB pathways was found in
IRAK4+/- mice compared to WT mice.
While IRAK4 overexpression signiﬁcantly attenuated cardiomyoblasts hypertrophy
induced by AngII accompaning with decreased expression of hypertrophic markers,
including atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and
decreased activation of the MEK-ERK1/2, p38 and NFkB pathways.
Conclusions: IRAK4 may play a crucial role in the development of cardiac remod-
eling via negative regulation of mutiple signaling pathways.
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Objectives: Diabetes is high risk factor for cardiovascular disease including athero-
sclerosis and coronary heart disease. Vascular endothelial dysfunction is the initiating
factor and early manifestation of diabetic vascular disease. Our preliminary study has
shown that sphingosine-1-phosphate (S1P) was signiﬁcantly increased in serum of
diabetic rats. sphingosine-1-phosphate receptor type 2 (S1PR2) was the overwhelming
S1P receptor expressing in human coronary artery endothelial cells (HCAECs)
exposed to high glucose condition. The present study explored the role of S1P/S1PR2
in diabetic vascular endothelial dysfunction and underlying mechanism, which may
provide S1P/S1PR2 pathway as therapeutic target to prevent and treat vascular
endothelial dysfunction in diabetes mellitus.
Methods: NO level, endothelial nitric oxide synthase (eNOS), intercellular adhesion
molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) protein
expression were measured in HCAECs by commercial kit and western blot, respec-
tively. MiRNA-31 level was detected by real-time PCR. After treatment by different
methods including S1PR2 speciﬁc antagonist, small molecular RNA interference,
overexpression of S1PR2, tranfection of miRNA mimic and inhibitor respectively, the
above indexes of endothelia cells function were investigated in HCAECs cultured
under 25mM high glucose condition. The target gene of miRNA-31 was predicted
using microRNA on-line analysis software and validated by dual-luciferase reporter
gene system and western blot.
Results: NO level and eNOS protein level were decreased, ICAM-1 and VCAM-1
protein level were increased signiﬁcantly in HCAECs by S1P treatment or S1PR2
overexpression. The enhanced NO level and eNOS protein as well as the decreasedJACC Vol 64/16/Suppl C j October 16–19, 2014 j GW-ICC Abstracts/BICAM-1 and VCAM-1 protein expression were observed after treatment with
sphingosine kinase-1 inhibitor DMS, S1PR2 speciﬁc antagonist JTE-013 and speciﬁc
S1PR2-siRNA respectively in HCAECs induced by S1P under high glucose condi-
tion. MiRNA-31 expression in indicated cells induced by S1P was also inhibited by
JTE-013 and S1PR2-siRNA. Moreover, the HCAECs co-transfected S1PR2-siRNA
and miRNA-31 mimic were shown the decreased in NO level and eNOS protein level
while the increased in adhesion molecule protein expression including ICAM-1 and
VCAM-1. The reversal effects were found in HCAECs overexpressed S1PR2 and
transfected miRNA-31 inhibitor together. Additionally, microRNA on-line analysis
software was used to predict the target of miRNA-31 and found that there was possible
binding sequence of miRNA-31 in human eNOS mRNA 3’-UTR. Furthermore, the
result of dual luciferase reporter gene experiment shown that the luciferase activities
were inhibited by overexpressed miRNA-31 at the presence of the wild type human
eNOS mRNA 3’-UTR, which can be abrogated by mutations in seed complementary
site. Protein expression of eNOS in miRNA-31 transduced cells was examined to be
suppressed after miRNA-31 transfection. Together, our results demonstrated that
eNOS was direct target of miRNA-31.
Conclusions: S1P/S1PR2 mediated vascular endothelial cells dysfunction by upre-
gulating miRNA-31 expression in HCAECs exposed to high glucose.
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Objectives: To study the association of platelet membrane glycoprotein poly-
morphism (GP I aC807T, GP I baKOZAK-5T/C, GP VI T13254/C, HPA-1 and HPA-
2) and coronary heart disease (CHD).
Methods: A case-control study design was adopted. The study group consisted of
150 patients (mean age¼63.9110.45 year) with coronary artery disease identiﬁed
by coronary angiography and 153 individuals (mean age¼64.6510.80 year)
without coronary artery disease. A newly-developed technology named improved
Multiplex Ligation Detection Reaction, iMLDR, was used to detect target genes and
SNPs. The risk factors for coronary artery disease were analyzed by logistic
regression.
Results: (1) For GP I aC807T, the comparisons of genotype and allele distributions
between cases and controls were signiﬁcant statistically (X2¼6.640, P¼0.036 and
X2¼5.725,P¼0.017, respectively). But for GP I baKOZAK-5T/C, GP VI T13254/C,
HPA-1 and HPA-2, the distributions of genotypes and alleles were not different
signiﬁcantly between cases and controls respectively. (2) Even adjusted by gender,
blood glucose, ﬁbrinogen and triglyceride, still the results from logistic analysis
showed that more than 4 times risks for coronary artery disease were increased by TT
genotype than CC genotype of GP I aC807T. (3) An association between mutant allele
numbers of platelete membrane glycoprotein included in this study and coronary
lesion was found by logistic regression analysis (OR¼1.36,P¼0.008,95%CI¼1.082-
1.707).
Conclusions: Even though traditional risk factors were still important causes of
coronary artery disease, the genetic risk factors should not be neglected. The poly-
morphism of GP I aC807T correlates signiﬁcantly with coronary artery disease, and
TT genotype is independent risk factor for coronary artery disease.
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Objectives: AngiotensinII (AngII) as an important pro-inﬂammatory factor pro-
motes the pathogenesis of hypertension remarkably, regardless in arteries or hearts.
The activation of Toll-like receptor 4 (TLR4) is one of key pathogenic factors of
the development of hypertension via expressing different kinds of cytokines.
Peroxisome proliferator-activated receptorg (PPARg) has been proved to play a
crucial role in the negative regulation of inﬂammation in many organs and the
growing evidences exhibit that the beneﬁts of PPARg agonists in hypertension
may been via its anti-inﬂammatory and antiﬁbrotic effects. The present study
evaluated the regulation of AngII-induced inﬂammatory responses by pioglitazone
both in vivo and vitro.
Methods: Hypertension spontaneous rats (SHRs) and Wistar Kyto rats (WKYs) were
treated with pioglitazone or saline for 8 weeks. Left ventricular tissues were harvest
for further analysis. Real-time RT-PCR, immunohistochemistry, western blot and
ELISA assay were performed in cultured cardiac ﬁbroblast cells or heart tissue. MTT
assay and ﬂow cytometry were used to measure cell proliferation.
Results: The rise of systolic blood pressure in SHRs was attenuated by pioglitazone.
In SHRs, the generation of monocyte chemotactic protein-1 (MCP-1), tumor necrosis
factor-a (TNF-a), TLR4, myeloid differentiation primary response gene 88 (Myd88)
and Nuclear factor kB (NF-kB) were remarkably increased; however, cotreatment
with pioglitazone diminished these changes and increased the nuclear-PPARg
expression. Treatment of CFs with TLR4 small-interfering RNA (siRNA) show thatasic and Translational Medicine C13
